Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBI-921352 in SCN8A Developmental and Epileptic Encephalopathy
NCT04873869Phase 2Terminated
- Sponsor
- Neurocrine Biosciences
- Start
- Jan 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zandatrigine in SCN8A developmental and epileptic encephalopathy (SCN8A-DEE), sponsored by Neurocrine Biosciences. Started Jan 2022; status: terminated.
02
Drugs
zandatrigine
03
Conditions
SCN8A developmental and epileptic encephalopathy (SCN8A-DEE)
Beyond the preview
Go deeper on NCT04873869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04873869.